DOH reports 11,000 new dengue cases | Inquirer News

DOH reports 11,000 new dengue cases

/ 07:50 AM March 02, 2018

Amid the controversy surrounding the dengue vaccine Dengvaxia, the Department of Health (DOH) on Thursday disclosed that about 11,000 dengue cases had been reported in the first six weeks of the year.

According to the DOH Dengue Disease Surveillance Report, a total of 10,980 dengue cases were reported from Jan. 1 to Feb. 10.

A total of 51 deaths had also been recorded for 2018, the DOH report added.

Article continues after this advertisement

But the number of dengue cases was 41.38 percent lower than the 18,731 cases reported within the same period last year, the report said.

FEATURED STORIES

It also noted that most of the dengue cases were recorded in areas where the mass dengue vaccination program was implemented.

There were 2,503 cases reported in Calabarzon, 1,964 cases in Central Luzon, and 1,820 cases in the National Capital Region.

Article continues after this advertisement

Except for the Ilocos Region, Cordillera Administrative Region (CAR), and Calabarzon, all other regions in the country were found to have a decreasing number of dengue cases.

Article continues after this advertisement

The Ilocos Region reported a 121-percent increase in the number of dengue cases; CAR had a 55 percent increase; and Calabarzon, 25 percent.

The report also showed that 23 percent of those afflicted with dengue were 10-14 years old.—TINA G. SANTOS

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our daily newsletter

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

TAGS: Calabarzon, dengue, Dengvaxia, DoH

Your subscription could not be saved. Please try again.
Your subscription has been successful.

Subscribe to our newsletter!

By providing an email address. I agree to the Terms of Use and acknowledge that I have read the Privacy Policy.

© Copyright 1997-2024 INQUIRER.net | All Rights Reserved

This is an information message

We use cookies to enhance your experience. By continuing, you agree to our use of cookies. Learn more here.